Literature DB >> 21410943

A study to investigate the role of p27 and cyclin E immunoexpression as a prognostic factor in early breast carcinoma.

Komala Pillay1, Heather McCleod, Runjan Chetty, Pauline Hall.   

Abstract

BACKGROUND: Cyclin E and p27 expression is easy to assess in human tissues by standard immunohistochemical techniques. Immunohistochemistry is cost effective, relatively easy to perform and will play more of a role in the future management of cancer. The aim of this study was to investigate the role of p27 and cyclin E immunoexpression as a prognostic factor in early breast carcinoma.
METHODS: Cyclin E and p27 immunohistochemistry was performed on sixty six cases of breast carcinoma submitted over a five year period to the Division of Anatomical Pathology, Groote Schuur hospital; Whittaker and Associates; and PathCare. All tumours included in this study were less than 5 cm in diameter (pT1 and pT2 stage) and all the patients had wide local excisions performed. Follow up information was obtained from patient folders in the Department of Radiation Oncology.
RESULTS: There was no significant association of cyclin E and p27 expression with distant metastasis free survival (MFS) for all invasive carcinomas in contrast to grade, lymph node spread and vascular invasion. However, there was a statistically significant direct association of cyclin E with distant metastases in all invasive carcinomas, in the subgroup of infiltrating duct carcinomas (IDC) and in the node negative group when cyclin E was stratified as negative and positive (low/high). In this study of early breast carcinoma, only 9/66 cases showed cyclin E expression. Of these, four patients had distant metastases, one patient had a local recurrence and four patients were alive at last follow-up. Furthermore, cyclin E expression was significantly associated with grade, lymph node spread, oestrogen receptor status and histological type. None of the lobular carcinomas showed cyclin E positivity and only one case of lobular carcinoma presented with distant metastases.59/66 cases were positive (low/high) for p27 while seven cases were negative, 22 cases showed low expression and 37 cases demonstrated high p27 expression.p27 was significantly associated with oestrogen receptor status only for all invasive carcinomas and in the IDC group. There was no statistical relationship between p27 and cyclin E, but 50 (76%) tumours with positive p27 expression were negative for cyclin E. There were similar results for the invasive ductal carcinoma subgroup.
CONCLUSION: This study shows that p27 and cyclin E are not good independent prognostic markers for early breast carcinoma in contrast to grade, lymph node spread and vascular invasion for all invasive carcinomas. However, cyclin E provides some prognostic value as there is a direct statistical association with the development of distant metastases. Many previous studies have correlated overexpression of cyclin E with an aggressive course. The inverse relationship between p27 and cyclin E expression which has been reported in the literature has been highlighted, but this was not statistically significant. Most cases showed positive p27 expression and negative Cyclin E expression. This may be due to the early stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21410943      PMCID: PMC3069943          DOI: 10.1186/1477-7819-9-31

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  31 in total

1.  [The effects of cyclin E on the growth and other cell cycle related genes of breast carcinoma cells MCF-7].

Authors:  M Huang; S Yang; S Liao; B Zhang; J You
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  2000-06

2.  Cyclin E and p27/Kip1: two proteins on a see-saw or another false dawn?

Authors:  R Chetty
Journal:  Histopathology       Date:  2002-04       Impact factor: 5.087

Review 3.  p27 Expression, a cyclin dependent kinase inhibitor in breast carcinoma.

Authors:  M Barbareschi
Journal:  Adv Clin Path       Date:  1999-10

4.  Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients.

Authors:  W Reed; V A Flørems; R Holm; E Hannisdal; J M Nesland
Journal:  Virchows Arch       Date:  1999-08       Impact factor: 4.064

5.  Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia.

Authors:  T K Said; R C Moraes; U Singh; F S Kittrell; D Medina
Journal:  Cell Growth Differ       Date:  2001-06

6.  Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer.

Authors:  H K Kim; I A Park; D S Heo; D Y Noh; K J Choe; Y J Bang; N K Kim
Journal:  Eur J Surg Oncol       Date:  2001-08       Impact factor: 4.424

Review 7.  Cell cycle control in breast cancer cells.

Authors:  C Elizabeth Caldon; Roger J Daly; Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Cell Biochem       Date:  2006-02-01       Impact factor: 4.429

8.  Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications.

Authors:  R Donnellan; I Kleinschmidt; R Chetty
Journal:  Hum Pathol       Date:  2001-01       Impact factor: 3.466

9.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Authors:  Incheol Shin; F Michael Yakes; Federico Rojo; Nah-Young Shin; Andrei V Bakin; Jose Baselga; Carlos L Arteaga
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

10.  Genetic instability promotes the acquisition of chromosomal imbalances in T1b and T1c breast adenocarcinomas.

Authors:  H Blegen; B M Ghadimi; A Jauho; A Zetterberg; E Eriksson; G Auer; T Ried
Journal:  Anal Cell Pathol       Date:  2001       Impact factor: 2.916

View more
  8 in total

1.  Biofunctional characteristics of in situ and invasive breast carcinoma.

Authors:  Sara Bravaccini; Anna Maria Granato; Laura Medri; Flavia Foca; Fabio Falcini; Wainer Zoli; Monica Ricci; Giuseppe Lanzanova; Nestory Masalu; Luigi Serra; Federico Buggi; Secondo Folli; Rosella Silvestrini; Dino Amadori
Journal:  Cell Oncol (Dordr)       Date:  2013-06-27       Impact factor: 6.730

2.  Prediction of Key Candidate Genes for Platinum Resistance in Ovarian Cancer.

Authors:  Kaidi Guo; Li Li
Journal:  Int J Gen Med       Date:  2021-11-16

3.  Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.

Authors:  Cansu Karakas; Anna Biernacka; Tuyen Bui; Aysegul A Sahin; Min Yi; Said Akli; Jolie Schafer; Angela Alexander; Opoku Adjapong; Kelly K Hunt; Khandan Keyomarsi
Journal:  Am J Pathol       Date:  2016-05-13       Impact factor: 4.307

4.  Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.

Authors:  Satu Luhtala; Synnöve Staff; Minna Tanner; Jorma Isola
Journal:  Tumour Biol       Date:  2016-01-26

5.  P27 expression in pleomorphic salivary gland adenoma.

Authors:  Bassel Tarakji; Ayesha Umair; Mohammed Alsakran Altamimi; Saleh Nasser Azzeghaiby; Abla Sayed Mahmoud; Shourouk Darwish; Mohammad Zakaria Nassani; Nipun Ashok
Journal:  Contemp Oncol (Pozn)       Date:  2014-09-23

6.  DEC1 regulates breast cancer cell proliferation by stabilizing cyclin E protein and delays the progression of cell cycle S phase.

Authors:  H Bi; S Li; X Qu; M Wang; X Bai; Z Xu; X Ao; Z Jia; X Jiang; Y Yang; H Wu
Journal:  Cell Death Dis       Date:  2015-09-24       Impact factor: 8.469

7.  Protein expression patterns of cell cycle regulators in operable breast cancer.

Authors:  Flora Zagouri; Vassiliki Kotoula; George Kouvatseas; Maria Sotiropoulou; Triantafyllia Koletsa; Theofani Gavressea; Christos Valavanis; Helen Trihia; Mattheos Bobos; Georgios Lazaridis; Angelos Koutras; George Pentheroudakis; Pantelis Skarlos; Dimitrios Bafaloukos; Niki Arnogiannaki; Sofia Chrisafi; Christos Christodoulou; Pavlos Papakostas; Gerasimos Aravantinos; Paris Kosmidis; Charisios Karanikiotis; George Zografos; Christos Papadimitriou; George Fountzilas
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

8.  Cell Culture Models and Pharmacological Perspective for the Study of Breast Cancer Markers.

Authors:  Cristian Layton Tovar; Hugo Mendieta Zerón
Journal:  EJIFCC       Date:  2013-07-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.